Somatopause Treatment is a specific clinical intervention aimed at reversing the physiological state of Somatopause, which is the age-related decline in the secretion of Growth Hormone (GH) and its downstream mediator, Insulin-like Growth Factor 1 (IGF-1). The treatment seeks to restore the somatotropic axis function to a more youthful level, thereby improving body composition, bone mineral density, and overall metabolic profile. This is a targeted, restorative approach within the broader field of age management and precision endocrinology.
Origin
The term is derived from ‘Somatopause,’ coined to describe the functional cessation or decline of the somatotropic axis, paralleling the terms menopause and andropause. The treatment aspect arose from the clinical potential of GH-releasing peptides to safely and physiologically address this deficiency without the risks associated with exogenous GH.
Mechanism
Treatment typically involves the administration of Growth Hormone-Releasing Peptides (GHRPs) or Growth Hormone-Releasing Hormone (GHRH) analogs, which act on the pituitary gland to stimulate the natural, pulsatile release of endogenous GH. This pulsatile release, unlike continuous exogenous GH administration, minimizes the risk of negative feedback and side effects. The resulting increase in circulating IGF-1 then mediates the anabolic effects on muscle, bone, and connective tissues, improving systemic function and vitality.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.